Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Deucravacitinib by Bristol-Myers Squibb for Ulcerative Colitis: Likelihood of Approval
Deucravacitinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase...
Deucravacitinib by Bristol-Myers Squibb for Hidradenitis Suppurativa: Likelihood of Approval
Deucravacitinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase...
Deucravacitinib by Bristol-Myers Squibb for Unspecified Dermatological Disorders: Likelihood of Approval
Deucravacitinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Unspecified Dermatological Disorders. According to GlobalData,...
Deucravacitinib by Bristol-Myers Squibb for Rosacea: Likelihood of Approval
Deucravacitinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Rosacea. According to GlobalData, Phase II...